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Objectives: Autoantibodies and aberrant immune complexes are pathological hallmarks
of systemic lupus erythematosus (SLE). This study aimed to determine the occurrence
of IgG autoantibodies against human serum albumin (anti-HSA IgG) and their potential
association with antibodies against bovine serum albumin (anti-BSA IgG) in patients with
SLE.
Methods: Sera of 180 SLE patients included to the Swiss SLE Cohort Study and
188 age- and sex-matched healthy controls were evaluated. Levels of anti-HSA IgG and
anti-BSA IgG were quantified by ELISA. Selected samples were further characterized
using serum fractions obtained by fast liquid chromatography (FPLC).
Results: SLE patients had increased levels of anti-HSA IgG (p= 0.002) but similar levels
of anti-BSA IgG compared to matched healthy controls. Anti-HSA IgG levels correlated
with the SLE Disease Activity Index (SLEDAI), which was more pronounced in patients
with an physician’s global assessment (PGA) of ≥ 1 (r = 0.309, p = 0.0066). Anti-HSA
IgG was partially complexed with serum albumin but also occurred as monomeric
autoantibodies in highly positive SLE patients. A positive correlation between anti-HSA
IgG and anti-BSA IgG was found that was stronger in SLE patients than in healthy
controls (r = 0.3172, p< 0.001 vs. r = 0.2122, p< 0.0035). Binding of anti-BSA IgGwas
inhibited partially in the presence of HSA in samples with double positivity for anti-HSA
and anti-BSA (median inhibition 47.9%, range 0.9–100%) and vice versa.
Conclusion: In SLE patients there is an increased prevalence of anti-HSA IgG
antibodies that are associated with SLE disease activity.
Keywords: antibodies, human serum albumin, patients, systemic lupus erythematosus, multicenter study
INTRODUCTION
Systemic lupus erythematosus (SLE), particularly frequent in women of childbearing age, has a
highly variable clinical presentation with flares and remissions. Pathogenic mechanisms leading
to SLE are still not fully understood. A hallmark of SLE is the occurrence of a broad spectrum
of antibodies targeting self-antigens. Although it still remains unclear how ubiquitous molecules
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become autoantigens, there is good evidence that autoantibody
production in SLE is antigen driven (1). One major but not
exclusive hypothesis is that apoptotic cells and defects in their
clearance are the origin for autoantigens and thus a trigger for
the autoimmune response. Apoptotic cells are identified, taken
up and degraded by professional and/or neighboring phagocytes
(2). The mechanisms underlying the recognition and engulfment
of these cells involves many receptors, bridging molecules, and
signal cascades among which complement seems to play a
prominent role (3). A defective clearance of apoptotic material
might induce an aberrant immune response leading to the
generation of a large number of autoantibodies (4).
So far, SLE is the autoimmune disease with the largest diversity
of detectable autoantibodies with more than 180 different
specificities having been described, but only a few have been
shown to be directly involved in tissue injury (5–7). However,
published investigations on human’s most abundant protein in
plasma, i.e., albumin, as an autoantigen are scarce. As a target
of autoantibodies, albumin would not obviously fit with the
hypothesis of an impaired clearance of apoptotic cells as a trigger
for the development of SLE. While albumin was found to protect
human endothelial cells from apoptosis, an albumin overload has
been shown to induce apoptosis in renal tubular cells (8–12).
Functionally, in spite of only two major binding sites albumin
shows diverse affinities, e.g., for hydrophobic ligands like fatty
acids, bilirubin, trace elements, hormones or pharmaceutical
substances (13). Though albumin plays major physiological roles
(carrier protein, regulation of blood pressure, stabilization of
blood pH etc.), rare cases of individuals were described that
essentially lacked albumin and exhibited only minor symptoms,
thus questioning the importance of the molecule (13). With
regard to a potential origin of autoantibodies against HSA, it is
of interest to note that HSA shares almost 80% sequence identity
with bovine serum albumin (BSA), which is present in western
diet (14). Previous studies (15–17) focused on the possibility
of BSA to be a causative agent for the onset of autoimmune
diseases, but the definite role of BSA in autoimmunity remains
to be established. More specifically, cross-reactivity between
BSA and human autoantigens, e.g., collagen type I, vitamin D
binding protein, myelin basic protein and islet beta cells, has
been reported in patients with rheumatoid arthritis, multiple
sclerosis, and diabetesmellitus. Furthermore, amore recent study
described a pathogenic role for cationic BSA in patients with
early-childhood membranous nephropathy (18). As for anti-
HSA, data on anti-BSA in patients with SLE are scarce.
Therefore, our study aimed to assess the occurrence of
autoantibodies against human serum albumin (anti-HSA) and
their potential association with antibodies against bovine serum
albumin (anti-BSA) in a large and well-defined cohort of SLE
patients compared to age- and sex-matched healthy controls.
MATERIALS AND METHODS
Patients and Clinical Data
Blood samples of 180 patients suffering from SLE and fulfilling
at least 4 of the 11 classification criteria of the American
College of Rheumatology (ACR) were provided by the Swiss
Systemic lupus erythematosus Cohort Study (SSCS) (19). The
samples were consecutively collected between 2008 and 2013 at
the University Hospitals in Basel, Bern, Geneva, and Lausanne
(all in Switzerland). The collection of clinical data followed a
standardized form and was recorded anonymously in an online
database after having obtained written informed consent from all
participating patients and clearance from the Ethical Committees
of the involved institutions. In our cross-sectional study, only
samples collected at the first study visit were analyzed.
The SLE patients had a median age of 42 years (range 16–84,
85% female), a median disease duration of 6 years since diagnosis
and a median SLE Disease Activity Index (SLEDAI) score of 4
at the time of blood sampling. The patient characteristics are
summarized in Table 1.
Serum specimens were also obtained from 188 age- and
gender-matched healthy blood donors having a median age of 49
years (range 19–81, 85.6% female). Blood samples from patients
and healthy controls were aliquoted and frozen at −80◦C until
further use.
Inclusion criteria of SLE patients for this study were: Age ≥
18 years with at least 4 classification criteria according to the
American College of Rheumatology (ACR), complete clinical
data for judgement of disease activity, availability of blood
samples and signed informed consent. There were no specific
exclusion criteria. The clinical manifestations were assessed in
accordance with the SLEDAI.
SSCS was approved by the responsible ethical committees of
all contributing centers.
Antigens and Detection of Antibodies
Antibodies were detected by ELISA using ninety-six well plates
(Maxi sorp, Thermo Denmark) that were coated with HSA and
TABLE 1 | Characteristics of 180 patients with systemic lupus erythematosus.
Number of patients, n 180
Female, n (%) 153 (85)
Male, n (%) 27 (15)
Age, median (range) 42 (16–84)
Disease duration at inclusion time, median (range) 6 (0-52.17)
Anti-dsDNA antibodies positive, n (%) 161 (92.8)
Complement C3 (g/L), median (range) (norm value
0.8–1.8 g/L)
0.73 (0.27–1.95)
Complement C4 (g/L), median (range) (norm value
0.1–0.4 g/L)
0.11 (0.02–0.47)
SLEDAI, median (range) 4 (0–38)
SLICC-SDI, median (range) 0 (0–9)
History of nephritis, n (%) 56 (31)
History of arthritis, n (%) 41 (23)
Systemic corticosteroids, n (%) 109 (61)
Antimalarial agents, n (%) 113 (63)
Immunosuppressant agents, n (%) 80 (44)
Anti-dsDNA, anti-double stranded deoxyrubinucleic acid antibodies; SLEDAI, SLE
Disease Activity Index; SLICC-SDI, Systemic Lupus International Collaborating Clinics-
SLE Damage Index.
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BSA as antigen respectively [both from Sigma-Aldrich USA;
HSA: A8763, i.e., ≥99% pure and essentially free of globulins;
BSA: A7906 and A7030 (protease free, fatty acid free, essentially
globulin free)] at a concentration of 2µg/ml diluted in coating
buffer (0.2M Carbonate buffer pH 9.6) overnight at 4◦C.
After washing with Phosphate Buffered Saline (PBS,
homemade) containing 0.05% Tween 20 (Sigma-Aldrich, USA)
(PBST), we applied patient and healthy control sera (centrifuged
for 30min at 4◦C at 2,1000 g) diluted 1/50 either in PBS Tween 20
(containing 0.14M NaCl, Gibco) or in PBS Tween 20 containing
1M NaCl (in order to reduce low affinity binding) in duplicates
followed by an incubation at room temperature (RT) for 1 h on a
plate shaker (Sarstedt TPM-2, 400 rpm).
Bound antibodies were detected with a secondary goat anti-
human IgG (Fc gamma) specific antibody conjugated with
alkaline phosphatase (Jackson ImmunoResearch) followed by
alkaline phosphatase substrate (Sigma-Aldrich). The enzymatic
reaction was quantified after 20min at 405 nm by a microplate
biokinetics reader (BioTEK Instruments, USA).
Anti-BSA antibody levels were quantified in relative Units
(rU) based on serial dilutions of one serum of the healthy donor
“MO” having been found to have high levels of monomeric IgG
(see below) with high avidity for BSA (KD value= 6.45 × 10−10
as estimated by Scatchard plot analysis adapted to the method
described by Hulme et al. [(20), data not shown]. A dilution of
1/100 was considered to be equivalent to 1000 relative Units (rU).
Because of a lack of standard for the determination of anti-HSA
levels, only few positive signals for anti-HSA IgG in sera of both
groups, a similar antigen (HSA vs. BSA), and the use of the same
secondary antibody for the determination of anti-HSA IgG and
anti-BSA IgG respectively, we decided to also use the anti-BSA
IgG standard for the calculation of anti-HSA IgG levels.
Anti-BSA IgG and anti-HSA IgG levels < 1 rU corresponded
to the background of the assay and thus were considered to be
negative. This approach was chosen because of a lack of normal
distribution (not allowing a proper use of standard deviations)
and because of the possibility that normal individuals could be
positive for anti-albumin antibodies as well.
As a control, in order to exclude the presence of
DNA/nucleosomes as a potential source of falsely positive
signals (in spite of the high purity of the HSA preparation),
samples being positive for the presence of anti-HSA IgG were
also tested on HSA that was pretreated for 1 h at RT with
increasing amounts of DNAse up to a maximum of 100µg/ml
(DNAse I from bovine pancreas, Sigma-Aldrich USA, D5025).
Moreover, samples from two SLE patients and one
healthy control being positive for anti-HSA on ELISA were
also investigated by Western blot using purified reduced
and unreduced HSA as antigen (Sigma-Aldrich USA,
A8763). In short, reduced/unreduced albumin was loaded
on a 12% SDS Tris-Glycine gel (Biorad USA, 4561044),
then transferred on a nitrocellulose membrane (Biorad
USA, 1620115) and blocked using protein free blocking
buffer TBS+0.1% Tween 20. Then, sera diluted 1:200 in
TBS+0.1% Tween 20 were incubated for 1 h at RT and,
after washing, bound IgG was detected using a goat anti-
human IgG (Fc gamma) specific antibody conjugated with
horseradish peroxidase (Jackson ImmunoResearch USA,
109-035-008).
Characterization of Anti-HSA in a
Subgroup of SLE Patients and Healthy
Donors
To determine whether the detected anti-HSA IgG were
monomeric or complexed IgG, we fractionated serum of the
two SLE patients and serum of the healthy control with the
highest antibody levels by fast protein liquid chromatography
(FPLC, GE ÄKTApure 25 L1, Sweden) based on protein size
using a Superdex 200 Increase 10/300 GL column (GE, Sweden).
The fraction size was 0.4ml. All fractions then were analyzed
for the presence of anti-HSA IgG by ELISA as described
before.
As our anti-HSA IgG ELISA might only detect free anti-
HSA IgG antibodies but miss those antibodies that have
already bound to serum albumin, the serum fractions of
patients as well as of matched controls were also tested for
the presence of albumin (HSA)-IgG complexes. For this, we
established a “sandwich” ELISA using a goat polyclonal anti-
HSA antibody (Abcam, ab19180 anti-human serum albumin
antibody) as catching antibody and a AP-labeled goat anti-
human-Fc gamma chain (Jackson, 109-055-008) as detecting
antibody. Areas under the curve (AUC) of albumin (HSA)-IgG
were calculated in fractions positive for these complexes. Selected
samples of SLE patients (n = 8) and healthy controls (n = 8)
matched for total anti-HSA IgG and anti-BSA IgG levels were
used to determine potential differences between patients and
controls.
Last, having detected albumin (HSA)-IgG complexes by
ELISA in serum fractions that normally should not contain
albumin (i.e., having a molecular weight of > 100 kD),
the presence of albumin in these fractions was verified by
Western blot. For this, FPLC fractions of anti-HSA IgG positive
individuals (one patient and one donor) containing molecules
with an estimated molecular weight of >100 kD were loaded on
a 12% SDS Tris-Glycine gel (Biorad USA, 4561044) (reduced and
unreduced), and then transferred on a nitrocellulose membrane
(Biorad, 1620115). Albumin was detected by a combination of
a goat anti-human serum albumin antibody (Abcam UK, ab
19180) followed by a HRP-labeled monoclonal anti-goat/sheep
IgG antibody (Sigma, A9452).
Inhibition of Antibody Binding by the
Presence of Fluid Phase HSA and BSA
To analyze a potential cross-reactivity between anti-HSA IgG
and anti-BSA IgG, samples with double positivity (n = 27 for
SLE patients; n = 13 for healthy controls) were analyzed in the
presence or absence of an excess of fluid phase BSA or HSA.
Differences in signal intensity recorded in the presence of fluid
phase antigen, were considered to reflect cross-reactivity and
expressed as percentage of response according to the formula:
100/rU of plate-bound antibody × rU of bound antibody in
presence of fluid phase antigen.
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Statistical Analysis
All statistical analyses except the calculation of areas under the
curve (AUC) were performed using GraphPad Prism Version 7.
The calculation of AUC was performed by program R (package
“pracma”).
Because of an asymmetric distribution, data are expressed
as median with range. Differences between two groups were
analyzed by two-tailed Mann-Whitney test or Fisher exact test
for unrelated data and Wilcoxon matched-pairs signed rank test
for matched samples. Correlations were analyzed by Spearman’s
rank correlation coefficient. P-values below 0.05 were considered
to be statistically significant.
RESULTS
Antibodies Against Albumin (Anti-HSA IgG)
in SLE Patients and Healthy Controls
Thirty-two of the 180 SLE patients (17.8%) and 13/188
healthy controls (6.9%) were found to be positive for anti-
HSA IgG. The difference in the frequency of positive samples
between SLE patients and healthy controls was significant
(p = 0.002, Fisher exact test), and antibody levels in
SLE patients were significantly higher than in age- and
sex-matched healthy controls (p = 0.002, Mann–Whitney,
Figure 1A).
FIGURE 1 | Anti-HSA IgG levels in healthy controls (n = 188) and SLE patients (n = 180). There was a significant difference between healthy controls and SLE
patients regarding (A) anti-HSA IgG (p = 0.002). FPLC serum profiles and fractions using FPLC were tested by anti-HSA IgG antibody ELISA for the healthy control
with the highest anti-HSA IgG level (B), the SLE patient with the highest anti-HSA IgG level (C) and for the SLE patient with the second highest anti-HSA IgG level (D).
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Pretreatment of HSA with increasing concentrations of
DNAse up to 100µg/ml led to a maximum drop of signal
intensity of 21% in one of the SLE sera compared to 7% in sera
of healthy controls suggesting that DNA-containing material was
not a major confounder in our assay. Furthermore, anti-HSA
IgG levels did not correlate with total-IgG levels, neither in SLE
patients (r = −0.004034; p = 0.9571) nor in healthy controls
(r = −0.04186; p = 0.5684) suggesting that the occurrence of
anti-HSA IgG did not reflect polyclonal B-cell activation.
Characterization of Anti-HSA
We next sought to determine whether anti-HSA IgG in serum
were monomeric or complexed. For this, separate FPLC fractions
of the individuals with highest anti-HSA IgG levels were analyzed
for the occurrence of anti-HSA IgG allowing an estimation of the
size of the molecules leading to a positive test result.
Figure 1B illustrates a representative FPLC protein profile
of a healthy control serum (gray line). After incubation of the
collected fractions on an anti-HSA IgG ELISA, a signal peak
among molecules with an apparent size of about 900 kDa (e.g.,
IgM, complement C1q) could be observed (black line) indicating
that IgG antibodies reactive with HSA were either polymers
and/or complexed with antigen (possibly albumin-containing
immune complexes).
In contrast, as shown in Figures 1C,D, SLE patients showed
an additional signal overlapping with the monomeric IgG peak.
Thus, in SLE patients antibodies recognizing HSA can be found
in larger complexes but also in smaller complexes and as
monomeric IgG.
As this data suggested the presence of albumin-IgG complexes
in anti-HSA IgG positive sera, we next aimed to get an estimation
of the levels of albumin (HSA)-IgG complexes in selected sera
of patients vs. controls matched for anti-BSA IgG and anti-
HSA IgG levels. Figures 2A,B show representative profiles of
albumin (HSA)-IgG complexes in one SLE patient (Figure 2B,
dark line) and it’s control (Figure 2A, dark line). Interestingly,
SLE patients (n = 8) tended to have more albumin (HSA)-
IgG immune complexes than healthy controls (n = 8), but had
not significantly increased overall levels of albumin (HSA)-IgG
complexes compared to matched controls (Figure 2C, p = 0.25),
not even after normalization for either the peak IgG value, or
the peak HSA value or both (data not shown). Albumin (HSA)-
IgG complexes were also found in sera being negative for (free)
anti-albumin antibodies.
In order to verify the presence of albumin in FPLC serum
fractions containing molecules with an estimated molecular
weight of >100 kD, those fractions of two representative sera
(one SLE patient and one control) were analyzed for the presence
FIGURE 2 | Occurrence of albumin-IgG complexes in representative serum profiles (gray lines) after separation by FPLC of one of the healthy controls (A) and the
corresponding (matched for anti-BSA IgG and anti-HSA IgG levels) SLE patient (B). Both had high levels of anti-BSA IgG and anti-HSA IgG. The dark line indicated the
signal intensity for albumin (HSA)-IgG complexes with the area under the curve (AUC) being shaded (AUC of the healthy control = 2.60 vs. AUC of the matched SLE
patient = 4.21). (C) Demonstrates pooled data of 8 SLE patients and 8 healthy controls being matched for anti-HSA and anti-BSA levels as highlighted by the use of
different symbols. Overall, there was no significant difference between the SLE patients and their corresponding healthy controls, but the SLE patients tended to have
more albumin (HSA)-IgG immune complexes.
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of albumin by Western blot. In line with the ELISA data shown
in Figure 2 and as shown in Supplement Figures 1A–C, albumin
was detected in a high molecular weight range (in analogy to the
FPLC fractions) when samples were unreduced while reduction
of the samples led to a monomeric albumin band in the range of
70 kD.
Last, samples from two SLE patients and one healthy control
being positive for anti-HSA IgG by ELISA were also investigated
by Western Blot using purified reduced and unreduced HSA as
antigen. All three samples tested positive for IgG anti-HSA on
reduced HSA but not on unreduced albumin suggesting that
conformational epitopes on albumin are of critical importance
(Supplement Figure 2).
Association of Anti-HSA IgG With Clinical
and Biological Manifestations of SLE
Patients
We then addressed the question whether the presence of anti-
HSA IgG was associated with clinical and laboratory features
of SLE. As summarized in Table 2, no associations of anti-HSA
IgG were found with age, gender, history of lupus nephritis and
central nervous system involvement, respectively. However, anti-
HSA IgG were weakly associated with the occurrence of arthritis
(p = 0.011) and weakly correlated with overall disease activity (r
= 0.1858; p = 0.0128). This correlation was more pronounced
in patients with active disease as defined by a Physician’s Global
Assessment (PGA) ≥ 1 (r = 0.309; p = 0.0066; n = 76).
Furthermore, anti-HSA antibodies were found to correlate with
anti-dsDNA antibodies (r = 0.3119; p < 0.0001) and anti-
C1q antibodies (r = 0.2826; p = 0.0001) while no association
was observed with levels of complement C3 or C4 respectively.
Comparing SLE patients being positive for anti-HSA IgG with
those being negative, we found that anti-HSA IgG positive
patients had significantly higher levels of anti-dsDNA antibodies
(Figure 3A), anti-C1q antibodies (Figure 3B) and SLEDAI scores
(Figure 3C).
Association of Anti-HSA IgG With
Antibodies Against Bovine Serum Albumin
(Anti-BSA IgG)
Of the 180 SLE patients tested, 117 (65%) were positive for anti-
BSA IgG vs. 138 of the 188 healthy controls (73.4%) (median
in SLE: 45.4 rU vs. median in healthy controls: 86.8 rU). These
differences were not significant (p= 0.0738, Figure 4).
As for anti-HSA IgG, no correlation of anti-BSA IgGwith total
IgG was found (SLE patients: r = 0.08795; p = 0.2404, healthy
controls: r = 0.0974; p = 0.1733). Moreover, no correlation
was found between anti-BSA IgG and anti-dsDNA antibody
levels in SLE patients (r = 0.1438, p = 0.0541), and an only
weak correlation could be observed between anti-BSA IgG and
anti-C1q antibody levels (r = 0.1598, p= 0.0322).
However, anti-BSA IgG correlated with anti-HSA IgG levels.
This was more pronounced in SLE patients (r = 0.3172; p <
0.0001, Figure 5) than in healthy controls (r = 0.2122; p =
0.0035, data not shown). Interestingly, most of the SLE patient
sera with the highest titre of anti-HSA IgG also had the highest
TABLE 2 | Association and correlation of anti-HSA IgG.
Association of anti-HSA
IgG with:
Median AU of anti-HSA
IgG (range)
p-value
Anti-dsDNA antibodies ns
yes 0 (0–4097)
no 0 (0–3)
History of nephritis ns
yes 0 (0–1033)
no 0 (0–4097)
CNS manifestations ns
yes 0 (0–563.5)
no 0 (0–4097)
Correlation of anti-HSA
IgG with:
Spearman r p-value
Complement C3 r = −0.052 ns
Complement C4 r = −0.004 ns
Anti-C1q r = 0.283 p = 0.0001
Anti-dsDNA r = 0.312 p < 0.0001
SLEDAI (all patients, n =
180)
r = 0.186 p = 0.0128
SLEDAI with PGA≥1 (n =
76)
r = 0.309 p = 0.0066
Total IgG r = −0.004 ns
AU, arbitrary units; CNS, central nervous system; PGA, Physician’s Global Assessment;
IgG, Immunoglobulin G. Anti-HSA levels < 1 rU were considered to correspond to the
background of the assay and were set to 0.
titre of anti-BSA IgG, which was not the case in the healthy
control with the highest levels of anti-HSA IgG. Three SLE
patients had both, high titres of anti-HSA IgG and high titres of
anti-BSA IgG, and one patient (with the second highest antibody
level) had only low anti-BSA IgG.
Assuming the occurrence of cross-reactive antibodies, we next
tested whether anti-BSA IgG could be inhibited by the presence
of fluid phase HSA, or anti-HSA IgG by BSA in 27 SLE patients
and 13 healthy controls with double positivity. Overall, the
median inhibition of anti-BSA IgG by HSA was 52% (range 0–
99%). The median inhibition in SLE patients numerically was
slightly less pronounced (46%) than in the healthy controls (59%)
but this difference was not significant (p = 0.6482, Figure 6B).
Similarly, the median inhibition of anti-HSA IgG by BSA was
68% (range 0–96%) with the median inhibition being more
pronounced in SLE patients (74%) than in healthy controls
(48%) (Figure 6A). Again, this difference was not significant
(p = 0.2751). The relative inhibition of anti-BSA IgG by fluid
phase HSA and of anti-HSA IgG by fluid phase BSA was dose
dependent.
Taken together, these data suggest that anti-albumin
antibodies are at least partially cross-reactive across species
(human-bovine).
DISCUSSION
This is the first systematic analysis of the occurrence of IgG
antibodies against HSA, the most abundant protein in plasma,
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FIGURE 3 | (A) Association of positivity/negativity for anti-HSA IgG with levels of anti-dsDNA antibodies in SLE patients. Anti-HSA IgG positive patients had
significantly higher levels of anti-dsDNA than anti-HSA IgG negative SLE patients [median of anti-HSA positive: 478 vs. median of anti-HSA IgG negative: 98.5;
p < 0.001 (Mann–Whitney)]. (B) Association of positivity/negativity for anti-HSA IgG with levels of anti-C1q antibodies in SLE patients. Anti-HSA IgG positive patients
had significantly higher levels of anti-C1q than anti-HSA IgG negative SLE patients [median of anti-HSA positive: 77.55 vs. median of anti-HSA negative: 14.9;
p < 0.001 (Mann–Whitney)]. (C) Association of positivity/negativity for anti-HSA IgG with the SLEDAI in SLE patients. Anti-HSA IgG positive patients had significantly
higher SLEDAI than anti-HSA IgG negative SLE patients [median of anti-HSA positive: 6 vs. median of anti-HSA negative: 4; p = 0.0108 (Mann–Whitney)].
and their association with clinical manifestations in patients
with SLE. Anti-HSA IgG antibodies were found to occur as
monomeric and as complexed antibodies. In spite of being
rather rare, in patients with SLE these anti-HSA IgG correlated
with overall disease activity, anti-dsDNA antibodies, anti-C1q
antibodies and a history of arthritis as shown in a large and
well-defined cohort of SLE patients. We also found that anti-
HSA IgG correlate with levels of anti-BSA IgG, which was more
pronounced in SLE patients than in controls. Among other
reasons for this association, this observation could be explained
by a possible cross-reactivity as we found a partial inhibition of
anti-HSA IgG by the presence of BSA and vice versa.
Thus far, antibodies targeting HSA were scarcely described.
Studies on anti-HSA antibodies were performed in small groups
of patients, particularly in patients with liver diseases (liver
cirrhosis, hepatitis B virus infection). In these patients, anti-
HSA antibodies were found to primarily belong to the IgM class
and to be complexed with HSA (21, 22). Another smaller study
on patients suffering from familial dysautonomia, a congenital
disorder of the autonomic nervous system, found an increased
level of antibodies against BSA as well. Due to the extensive
homology between BSA and HSA, the study also addressed
the occurrence of anti-HSA that were found to belong to the
IgM and IgG classes. In addition, a correlation between both,
anti-BSA and anti-HSA, was found suggesting that anti-HSA
could be induced by bovine milk antigens and recognized by
antibodies binding to antigenic epitopes common in BSA and
HSA (23).
Independently, glycosylated proteins have been described to
play a role in the development of autoantibodies (24–26). In this
context, Gregor et al. screened patients with insulin-dependent
diabetes for the presence of antibodies against glycosylated
albumin. While such a type of antibodies could not be detected,
again IgM antibodies against unmodified HSA were identified
(27).
In accordance with the results of previous studies, we also
identified antibodies targeting BSA and investigated whether
there was a relationship between anti-HSA IgG and anti-BSA IgG
in SLE. Besides the correlation between anti-HSA and anti-BSA
IgG, which was more pronounced in SLE patients, we could also
demonstrate a partial inhibition of anti-HSA IgG by the presence
of BSA and vice versa in individuals with double positivity for
anti-HSA and anti-BSA IgG. The reasons for this partial cross-
reactivity in our patients remain elusive and our data clearly do
not provide a definite explanation, in particular because anti-
BSA IgG were not increased in SLE patients. More complex
experimental studies are required to establish or abandon a direct
relationship between the two. One hypothesis could be that anti-
HSA and anti-BSA IgG both are the result of epitope spreading,
and that BSA can trigger or exacerbate the immune response
against HSA. Such a hypothesis has already been formulated
in previous studies. Another hypothesis is based on meat and
diary products in general that have been described as a possible
contributor to inflammatory responses, especially with regard
to arthritis in patients with rheumatic diseases. Based on both,
animal and human studies, it is assumed that proteins containing
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FIGURE 4 | Antibodies against bovine serum albumin in SLE patients (n =
180) and healthy controls (n = 188). There was no difference seen between
SLE patients and healthy controls regarding anti-BSA IgG concentration (p =
0.07, two-tailed Mann–Whitney). Bars represent median values.
high levels of phenylalanine and tyrosine, such as found in beef
and diary products, may modulate SLE symptoms, but data on
the role of these proteins are controversial (28, 29). With regard
to our study it is of interest to note that albumin also contains
aromatic amino acids.
Using in vivo models and in vitro experiments, BSA has been
shown to be involved in the development of arthritis due to
an interaction with synoviocytes, in animals and in humans
(30–34). Moreover, by means of a sequence alignment analysis,
Pérez-Maceda et al. demonstrated that specific residues of BSA,
which differed clearly from the corresponding fragment in HSA,
were highly homologous with human collagen type I, C1q and
vitamin D binding protein (16). Furthermore, representative sera
of patients were found to have specific antibodies against BSA.
Thus, it was assumed that the pathogenic mechanism of BSA in
arthritis is explained by molecular mimicry.
Furthermore, in multiple sclerosis patients an association
between anti-BSA antibodies and myelin basic protein has been
reported by Winer et al. that is based on a structural homology
between the two (17). The authors discussed an etiological role
for BSA in the pathogenesis of multiple sclerosis comparable
to studies with insulin dependent diabetic patients (IDDM) in
which it was hypothesized that antibodies against food-derived
BSA result in a cross-reactivity and consecutive destruction of
beta cells (15, 35). Again, this view is controversial. More recent
studies found no clear evidence for this hypothesis and suggest
that the development of anti-BSA is part of a more general
immune response against foreign proteins (36–38).
FIGURE 5 | Correlation of anti-BSA IgG level and anti-HSA IgG level in all SLE
patients (n = 180). A significant correlation was seen between SLE patients
and healthy controls with a correlation coefficient r = 0.3172 by Spearman’s
rank correlation (p < 0.0001).
Last, as demonstrated in vivo, the intravenous injection
of cationic BSA (c-BSA) can cause lesions of membranous
nephropathy due to the deposition of immune complexes
containing anti-BSA IgG and complement component C3 (39–
41). Importantly, a more recent study by Debiec et al. could
validate in four children with early-childhood membranous
nephropathy a pathogenic role of c-BSA by the detection of high
levels of anti-c-BSA IgG antibodies, suggesting that food-derived
BSA may lead to glomerular lesions (18). In this context, it is
noteworthy that in our study 11 of the 20 SLE patients with the
highest anti-BSA IgG levels had a history of proliferative lupus
nephritis [6 × class IV, 4 × class III, 1 × class II based on
the International Society of Nephrology/Renal Pathology Society
(ISN/RPS) classification of lupus nephritis (42)] vs. 45 of the
remaining 160 patients (p= 0.0206, two tailed Fisher’s exact test).
If this observation can be confirmed it might be of relevance with
regard to recommendations on diet in SLE patients, especially for
patients with lupus nephritis.
Taken together, considering food-derived BSA as a causative
factor for the association between anti-HSA and anti-BSA
remains speculative and our observational data do not provide
direct evidence for it. Other mechanisms might explain the
association between anti-HSA and anti-BSA IgG as observed
in our patients. For example, epitope spreading has been well-
described to lead to autoantibody diversification in experimental
models of SLE. Applying this concept to our observations, it is
also conceivable that both types of antibodies (anti-HSA IgG and
anti-BSA IgG) are the result of antibody spreading without any
sequential relationship between the two (43–45).
In addition, our study has other limitations. Despite having
analyzed a large cohort of patients, further studies are needed
for the validation of our results, in particular with regard to the
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FIGURE 6 | (A) Relative inhibition (percentage) of anti-HSA IgG by the presence of an excess in fluid phase BSA [median of SLE patients: 73.6 vs. healthy controls:
48.2, not significant (Mann–Whitney)]. (B) Relative inhibition (percentage) of anti-BSA IgG by the presence of an excess in fluid phase HSA [median of SLE patients:
46.1 vs. median of healthy controls: 58.6, not significant (Mann–Whitney)].
association between anti-HSA IgG and SLE disease activity. As
we only analyzed SLE patients and matched healthy controls,
we cannot estimate whether the occurrence of anti-HSA IgG is
lupus-specific. For this, studies on patients with other rheumatic
diseases (including rheumatoid arthritis and other connective
tissue disorders) will be required, ideally using matched controls.
Second, although we used highly pure HSA as a reagent in
our assays and in spite of attempts to address the topic by
using different experimental techniques, we cannot fully exclude
that impurity of the albumin preparations (HSA as well as
BSA) might have partially influenced our signals. For example,
pretreatment of HSA with increasing concentrations of DNAse
led to a maximum drop of signal intensity of about 20% in one of
the SLE sera.
Third, as anti-HSA IgG autoantibodies target a soluble antigen
that is abundant in human plasma, an obvious question was
whether our assay was able to detect all or at least a relevant
and proportional part of the autoantibodies occurring in vivo
(21). Therefore, our study included efforts to (i) analyze how
much of the detected signal in our assay was the result of
immune-complexes (vs. monomeric autoantibodies), and (ii)
whether we missed a relevant part of autoantibodies that in
fact were complexed and thus could not be detected in the
ELISA. While the signal in our assay indeed largely consisted of
complexed IgG, in SLE patients we could also detect anti-HSA
IgG signals in the range of monomeric IgG suggesting that the
signal consisted of either free autoantibodies and/or very small
complexes. In addition, we analyzed the occurrence of albumin
(HSA) -IgG complexes comparing SLE patients with healthy
donors beingmatched for anti-HSA and anti-BSA IgG levels with
a focus on individuals with low or even negative antibody levels.
Interestingly, SLE patients tended to have more serum albumin
(HSA)-IgG complexes than their matched controls, but we could
not observe striking differences. This observation suggests that
we did not miss large parts of the anti-HSA antibodies. It is
important to note that albumin (HSA)-IgG complexes could also
be detected in patients that were negative for anti-HSA and anti-
BSA IgG respectively which might indicate, that the occurrence
of these complexes is at least partially unspecific or due to low
affinity interactions. However, we cannot exclude the possibility
that in fact most anti-HSA autoantibodies are rapidly cleared by
the reticuloendothelial system once being bound to their target.
To overcome this problem, studies focusing on autoantibody-
producing cells would be required. Last, our study was limited
to the determination of IgG anti-HSA and did not include the
analyses of other immunoglobulin classes. Here, beyond the
determination of IgM as outlined above, IgA antibodies might be
of particular interest. Increased levels of IgA as well as immune
complexes containing IgA were described to play a pathogenic
role based on the observation of increased cartilage erosion
and the occurrence of erosive arthritis in patients with high
levels of IgA, especially in patients with rheumatoid arthritis
(46, 47).
In conclusion, anti-HSA IgG were found to have an increased
prevalence in SLE patients and were associated with SLE disease
activity. Furthermore, anti-HSA IgGwere found to correlate with
levels of IgG antibodies against bovine serum albumin. Further
studies are required to determine the role of anti-HSA and anti-
BSA IgG in SLE, in particular with regard to their association with
lupus nephritis.
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